Palvella Therapeutics Completes $45 Million Series C Financing
WAYNE, PA — Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments, announced the closing …
Read More